Manganese Porphyrin and Radiotherapy Improves Local Tumor Response and Overall Survival in Orthotopic Murine Mammary Carcinoma Models.


Journal

Radiation research
ISSN: 1938-5404
Titre abrégé: Radiat Res
Pays: United States
ID NLM: 0401245

Informations de publication

Date de publication:
01 02 2021
Historique:
received: 17 04 2020
accepted: 06 10 2020
pubmed: 3 12 2020
medline: 23 4 2021
entrez: 2 12 2020
Statut: ppublish

Résumé

Novel synthetic compounds, known as manganese porphyrins (MnPs), have been designed to shift the redox status of both normal cells and cancer cells. When MnPs are coupled with cancer therapies, such as radiation, they have been shown to sensitize tumor cells to treatment and protect normal tissues from damage through the modulation of the redox status of various tissue types. Until now, our preclinical studies have focused on local effects of MnPs and radiation; however, we recognize that successful outcomes for cancer patients involve control of tumor cells throughout the body. In this study, using murine orthotopic mammary tumor models, we investigated how MnPs and radiation influence the development of distant metastasis. We hypothesized that the combination of MnP (MnP/RT), such as MnTnBuOE-2-PyP5+ and radiation treatment (RT) would increase local tumor control via a shift in the intratumoral redox environment, leading to subsequent downregulation of HIF-1 in the primary tumor. Secondarily, we hypothesized that these primary tumor treatment effects would result in a reduction in pulmonary metastatic burden. Balb/c mice with orthotopic 4T1 mammary carcinomas were treated with saline, MnP, RT or MnP/RT. We found MnP/RT did extend local tumor growth delay and overall survival compared to controls and was associated with increased intratumoral oxidative stress. However, the primary tumor growth delay observed with MnP/RT was not associated with a reduced pulmonary metastatic burden. Future directions to investigate the effects of MnP/RT on the development of distant metastasis may include modifications to the radiation dose, the experimental timeline or using a murine mammary carcinoma cell line with a less aggressive metastatic behavior. Clinical trials are underway to investigate the clinical utility of MnTnBuOE-2-PyP5+ for patients undergoing radiotherapy for various tumor types. The promising preclinical data from this study, as well as others, provides support that MnP/RT has the potential to improve local tumor control for these patients.

Identifiants

pubmed: 33264413
pii: 449009
doi: 10.1667/RADE-20-00109.1
pmc: PMC7962472
mid: NIHMS1672067
doi:

Substances chimiques

Metalloporphyrins 0
Porphyrins 0
Manganese 42Z2K6ZL8P

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

128-139

Subventions

Organisme : NCRR NIH HHS
ID : T32 RR024394
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA178888
Pays : United States
Organisme : NIH HHS
ID : T32 OD011130
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA040355
Pays : United States

Informations de copyright

©2021 by Radiation Research Society. All rights of reproduction in any form reserved.

Références

J Clin Oncol. 2000 Oct 1;18(19):3339-45
pubmed: 11013273
Chem Biol Interact. 2006 Mar 10;160(1):1-40
pubmed: 16430879
Inorg Chem. 2014 Nov 3;53(21):11467-83
pubmed: 25333724
J Clin Invest. 2013 May;123(5):2078-93
pubmed: 23563312
Antioxid Redox Signal. 2017 Nov 10;27(14):1067-1082
pubmed: 28358581
Free Radic Biol Med. 2008 Mar 15;44(6):982-9
pubmed: 18082148
PLoS One. 2015 May 19;10(5):e0127229
pubmed: 25993275
Cancer Res. 2007 May 1;67(9):4157-63
pubmed: 17483326
Antioxidants (Basel). 2018 Jan 25;7(1):
pubmed: 29370088
Carcinogenesis. 2006 Jun;27(6):1134-45
pubmed: 16474180
PLoS One. 2010 Nov 05;5(11):e13828
pubmed: 21079779
Cell Metab. 2005 Jun;1(6):393-9
pubmed: 16054088
Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):892-900
pubmed: 26530759
Antioxid Redox Signal. 2018 Nov 1;29(13):1196-1214
pubmed: 29390861
Cancer Res. 1999 Nov 15;59(22):5830-5
pubmed: 10582706
Science. 2016 Apr 8;352(6282):175-80
pubmed: 27124451
Cell Metab. 2005 Jun;1(6):409-14
pubmed: 16054090
J Control Release. 2015 Jun 28;208:52-8
pubmed: 25637704
Clin Breast Cancer. 2015 Dec;15(6):403-12
pubmed: 26198331
Redox Biol. 2019 Jul;25:101139
pubmed: 31126869
Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16369-74
pubmed: 21911388
Clin Exp Metastasis. 1999 Mar;17(2):163-70
pubmed: 10411109
Semin Cell Dev Biol. 2018 Aug;80:50-64
pubmed: 28587975
Mol Cancer Ther. 2015 Jan;14(1):70-9
pubmed: 25319393
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):545-52
pubmed: 16168847
Nat Rev Cancer. 2014 Nov;14(11):709-21
pubmed: 25342630
Nat Rev Clin Oncol. 2011 May 31;8(7):393-404
pubmed: 21629216
Oncogene. 2012 Apr 5;31(14):1757-70
pubmed: 21860410
Biochemistry. 1990 Aug 28;29(34):7876-82
pubmed: 2261442
Nat Rev Cancer. 2008 Jun;8(6):425-37
pubmed: 18500244
Antioxid Redox Signal. 2018 Dec 1;29(16):1691-1724
pubmed: 29926755
Free Radic Biol Med. 2012 May 1;52(9):1828-34
pubmed: 22336516
Biochim Biophys Acta. 2016 Mar;1863(3):382-391
pubmed: 26079100
Cell Metab. 2005 Jun;1(6):401-8
pubmed: 16054089
Antioxid Redox Signal. 2014 May 20;20(15):2372-415
pubmed: 23875805
Anticancer Res. 2007 Sep-Oct;27(5A):3101-9
pubmed: 17970050
Cancer Cell. 2004 May;5(5):429-41
pubmed: 15144951
Free Radic Biol Med. 2015 Dec;89:1231-47
pubmed: 26496207
J Exp Med. 1994 Aug 1;180(2):525-35
pubmed: 8046331
Nat Cell Biol. 2008 Mar;10(3):295-305
pubmed: 18297062
Tumour Biol. 2014 May;35(5):4401-9
pubmed: 24425106
Oncogene. 2010 Feb 4;29(5):625-34
pubmed: 19946328
Am J Pathol. 2000 Aug;157(2):411-21
pubmed: 10934146
Cancer Res. 2007 Jan 15;67(2):563-72
pubmed: 17234764

Auteurs

Mary-Keara Boss (MK)

Department of Environmental and Radiological Health Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523.

Rebecca E Oberley-Deegan (RE)

Department of b Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198.

Ines Batinic-Haberle (I)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710.

Geoffrey A Talmon (GA)

Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198.

Jason A Somarelli (JA)

Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.

Shengnan Xu (S)

Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.

Elizabeth A Kosmacek (EA)

Department of b Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198.

Brandon Griess (B)

Department of b Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198.

Shakeel Mir (S)

Department of b Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198.

Shashank Shrishrimal (S)

Department of b Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198.

Melissa Teoh-Fitzgerald (M)

Department of b Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska 68198.

Ivan Spasojevic (I)

Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.

Mark W Dewhirst (MW)

Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH